Etiology of angiogenesis inhibition-related hypertension
Current Opinion in Pharmacology , Volume 21 p. 7- 13
Angiogenesis inhibition, targeting vascular endothelial growth factor (VEGF) or its receptors, is an established treatment for solid tumors. A common side effect of this treatment is the development of sometimes severe hypertension. This hypertension is associated with a decrease in nitric oxide production, activation of the endothelin-signaling pathway and renin suppression. The mechanism underlying activation of the endothelin-signaling pathway is not fully understood. Both activation of endothelial cells and disinhibition of the VEGF-induced suppression of endothelin production by endothelial cells may be involved. The development of hypertension can be a reason to discontinue the angiogenesis inhibitor, thereby compromising anticancer treatment, but possibly is also a biomarker for a favorable antitumor response.
|Current Opinion in Pharmacology|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
Lankhorst, S, Saleh, L, Danser, A.H.J, & van den Meiracker, A.H. (2015). Etiology of angiogenesis inhibition-related hypertension. Current Opinion in Pharmacology (Vol. 21, pp. 7–13). doi:10.1016/j.coph.2014.11.010